Cargando…

Comparative Effectiveness of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Human Glucagon-Like Peptide-1 (GLP-1) Analogue as Add-On Therapies to Sulphonylurea among Diabetes Patients in the Asia-Pacific Region: A Systematic Review

The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers. Whereas some of the established oral hypoglycaemic drug classes li...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Martin C. S., Wang, Harry H. X., Kwan, Mandy W. M., Zhang, Daisy D. X., Liu, Kirin Q. L., Chan, Sky W. M., Fan, Carmen K. M., Fong, Brian C. Y., Li, Shannon T. S., Griffiths, Sian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948731/
https://www.ncbi.nlm.nih.gov/pubmed/24614606
http://dx.doi.org/10.1371/journal.pone.0090963
_version_ 1782306823236222976
author Wong, Martin C. S.
Wang, Harry H. X.
Kwan, Mandy W. M.
Zhang, Daisy D. X.
Liu, Kirin Q. L.
Chan, Sky W. M.
Fan, Carmen K. M.
Fong, Brian C. Y.
Li, Shannon T. S.
Griffiths, Sian M.
author_facet Wong, Martin C. S.
Wang, Harry H. X.
Kwan, Mandy W. M.
Zhang, Daisy D. X.
Liu, Kirin Q. L.
Chan, Sky W. M.
Fan, Carmen K. M.
Fong, Brian C. Y.
Li, Shannon T. S.
Griffiths, Sian M.
author_sort Wong, Martin C. S.
collection PubMed
description The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers. Whereas some of the established oral hypoglycaemic drug classes like biguanide, sulphonylureas, thiazolidinediones have been extensively used, the newer agents like dipeptidyl peptidase-4 (DPP-4) inhibitors and the human glucagon-like peptide-1 (GLP-1) analogues have recently emerged as suitable options due to their similar efficacy and favorable side effect profiles. These agents are widely recognized alternatives to the traditional oral hypoglycaemic agents or insulin, especially in conditions where they are contraindicated or unacceptable to patients. Many studies which evaluated their clinical effects, either alone or as add-on agents, were conducted in Western countries. There exist few reviews on their effectiveness in the Asia-Pacific region. The purpose of this systematic review is to address the comparative effectiveness of these new classes of medications as add-on therapies to sulphonylurea drugs among diabetic patients in the Asia-Pacific countries. We conducted a thorough literature search of the MEDLINE and EMBASE from the inception of these databases to August 2013, supplemented by an additional manual search using reference lists from research studies, meta-analyses and review articles as retrieved by the electronic databases. A total of nine randomized controlled trials were identified and described in this article. It was found that DPP-4 inhibitors and GLP-1 analogues were in general effective as add-on therapies to existing sulphonylurea therapies, achieving HbA1c reductions by a magnitude of 0.59–0.90% and 0.77–1.62%, respectively. Few adverse events including hypoglycaemic attacks were reported. Therefore, these two new drug classes represent novel therapies with great potential to be major therapeutic options. Future larger-scale research should be conducted among other Asia-Pacific region to evaluate their efficacy in other ethnic groups.
format Online
Article
Text
id pubmed-3948731
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-39487312014-03-13 Comparative Effectiveness of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Human Glucagon-Like Peptide-1 (GLP-1) Analogue as Add-On Therapies to Sulphonylurea among Diabetes Patients in the Asia-Pacific Region: A Systematic Review Wong, Martin C. S. Wang, Harry H. X. Kwan, Mandy W. M. Zhang, Daisy D. X. Liu, Kirin Q. L. Chan, Sky W. M. Fan, Carmen K. M. Fong, Brian C. Y. Li, Shannon T. S. Griffiths, Sian M. PLoS One Research Article The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers. Whereas some of the established oral hypoglycaemic drug classes like biguanide, sulphonylureas, thiazolidinediones have been extensively used, the newer agents like dipeptidyl peptidase-4 (DPP-4) inhibitors and the human glucagon-like peptide-1 (GLP-1) analogues have recently emerged as suitable options due to their similar efficacy and favorable side effect profiles. These agents are widely recognized alternatives to the traditional oral hypoglycaemic agents or insulin, especially in conditions where they are contraindicated or unacceptable to patients. Many studies which evaluated their clinical effects, either alone or as add-on agents, were conducted in Western countries. There exist few reviews on their effectiveness in the Asia-Pacific region. The purpose of this systematic review is to address the comparative effectiveness of these new classes of medications as add-on therapies to sulphonylurea drugs among diabetic patients in the Asia-Pacific countries. We conducted a thorough literature search of the MEDLINE and EMBASE from the inception of these databases to August 2013, supplemented by an additional manual search using reference lists from research studies, meta-analyses and review articles as retrieved by the electronic databases. A total of nine randomized controlled trials were identified and described in this article. It was found that DPP-4 inhibitors and GLP-1 analogues were in general effective as add-on therapies to existing sulphonylurea therapies, achieving HbA1c reductions by a magnitude of 0.59–0.90% and 0.77–1.62%, respectively. Few adverse events including hypoglycaemic attacks were reported. Therefore, these two new drug classes represent novel therapies with great potential to be major therapeutic options. Future larger-scale research should be conducted among other Asia-Pacific region to evaluate their efficacy in other ethnic groups. Public Library of Science 2014-03-10 /pmc/articles/PMC3948731/ /pubmed/24614606 http://dx.doi.org/10.1371/journal.pone.0090963 Text en © 2014 Wong et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Wong, Martin C. S.
Wang, Harry H. X.
Kwan, Mandy W. M.
Zhang, Daisy D. X.
Liu, Kirin Q. L.
Chan, Sky W. M.
Fan, Carmen K. M.
Fong, Brian C. Y.
Li, Shannon T. S.
Griffiths, Sian M.
Comparative Effectiveness of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Human Glucagon-Like Peptide-1 (GLP-1) Analogue as Add-On Therapies to Sulphonylurea among Diabetes Patients in the Asia-Pacific Region: A Systematic Review
title Comparative Effectiveness of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Human Glucagon-Like Peptide-1 (GLP-1) Analogue as Add-On Therapies to Sulphonylurea among Diabetes Patients in the Asia-Pacific Region: A Systematic Review
title_full Comparative Effectiveness of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Human Glucagon-Like Peptide-1 (GLP-1) Analogue as Add-On Therapies to Sulphonylurea among Diabetes Patients in the Asia-Pacific Region: A Systematic Review
title_fullStr Comparative Effectiveness of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Human Glucagon-Like Peptide-1 (GLP-1) Analogue as Add-On Therapies to Sulphonylurea among Diabetes Patients in the Asia-Pacific Region: A Systematic Review
title_full_unstemmed Comparative Effectiveness of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Human Glucagon-Like Peptide-1 (GLP-1) Analogue as Add-On Therapies to Sulphonylurea among Diabetes Patients in the Asia-Pacific Region: A Systematic Review
title_short Comparative Effectiveness of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Human Glucagon-Like Peptide-1 (GLP-1) Analogue as Add-On Therapies to Sulphonylurea among Diabetes Patients in the Asia-Pacific Region: A Systematic Review
title_sort comparative effectiveness of dipeptidyl peptidase-4 (dpp-4) inhibitors and human glucagon-like peptide-1 (glp-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the asia-pacific region: a systematic review
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948731/
https://www.ncbi.nlm.nih.gov/pubmed/24614606
http://dx.doi.org/10.1371/journal.pone.0090963
work_keys_str_mv AT wongmartincs comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview
AT wangharryhx comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview
AT kwanmandywm comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview
AT zhangdaisydx comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview
AT liukirinql comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview
AT chanskywm comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview
AT fancarmenkm comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview
AT fongbriancy comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview
AT lishannonts comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview
AT griffithssianm comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview